Anixa Biosciences Announces Timing of Public Release of Data from the Phase 1 Study of its Breast Cancer Vaccine at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting
Anixa Biosciences (NASDAQ: ANIX) announced that additional data from the Phase 1 clinical trial of its breast cancer vaccine will be made public on November 8, 2024, at 12:15pm CT. The presentation, titled 'Phase I Trial of alpha-lactalbumin vaccine in high risk operable triple negative breast cancer (TNBC) and patients at high genetic risk for TNBC,' will be presented at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting. The data will be available on the company's website, accompanied by a press release analyzing the results.
Anixa Biosciences (NASDAQ: ANIX) ha annunciato che ulteriori dati provenienti dal trials clinico di Fase 1 del suo vaccino per il carcinoma mammario saranno resi pubblici l'8 novembre 2024, alle 12:15 CT. La presentazione, intitolata 'Trial di Fase I del vaccino alpha-lattalbumina in pazienti con carcinoma mammario triplo negativo (TNBC) ad alto rischio operabile e pazienti ad alto rischio genetico per TNBC,' sarà presentata al 39° Congresso Annuale della Society for Immunotherapy of Cancer (SITC). I dati saranno disponibili sul sito web dell'azienda, accompagnati da un comunicato stampa che analizza i risultati.
Anixa Biosciences (NASDAQ: ANIX) anunció que se harán públicos datos adicionales del ensayo clínico de Fase 1 de su vacuna contra el cáncer de mama el 8 de noviembre de 2024 a las 12:15 p.m. CT. La presentación, titulada 'Ensayo de Fase I de la vacuna de alpha-lactalbumina en cáncer de mama triple negativo (TNBC) operable de alto riesgo y pacientes con alto riesgo genético para TNBC,' se presentará en la 39ª Reunión Anual de la Society for Immunotherapy of Cancer (SITC). Los datos estarán disponibles en el sitio web de la empresa, acompañados de un comunicado de prensa que analiza los resultados.
Anixa Biosciences (NASDAQ: ANIX)는 유방암 백신의 1상 임상 시험에 대한 추가 데이터가 2024년 11월 8일 오후 12시 15분 CT에 공개될 것이라고 발표했습니다. '높은 위험의 수술 가능한 삼중 음성 유방암(TNBC) 및 TNBC에 대한 높은 유전적 위험을 가진 환자에서 알파-락탈부민 백신의 1상 시험'이라는 제목의 발표가 39회 암 면역 요법 학회(SITC) 연례 회의에서 진행될 예정입니다. 데이터는 회사 웹사이트에서 제공되며 결과를 분석하는 보도 자료가 함께 제공됩니다.
Anixa Biosciences (NASDAQ: ANIX) a annoncé que des données supplémentaires de l'essai clinique de Phase 1 de son vaccin contre le cancer du sein seront rendues publiques le 8 novembre 2024 à 12h15 CT. La présentation, intitulée 'Essai de Phase I du vaccin alpha-lactalbumine chez des patientes à haut risque opérables de cancer du sein triple négatif (TNBC) et chez des patientes à haut risque génétique pour TNBC,' sera présentée lors de la 39e Réunion Annuelle de la Society for Immunotherapy of Cancer (SITC). Les données seront disponibles sur le site web de la société, accompagnées d'un communiqué de presse analysant les résultats.
Anixa Biosciences (NASDAQ: ANIX) gab bekannt, dass zusätzliche Daten aus der Phase-1-Studie ihres Impfstoffs gegen Brustkrebs am 8. November 2024 um 12:15 Uhr CT veröffentlicht werden. Die Präsentation mit dem Titel 'Phase-I-Studie des alpha-Lactalbumin-Impfstoffs bei hochriskant operablem triple-negativem Brustkrebs (TNBC) und Patienten mit hohem genetischen Risiko für TNBC' wird auf dem 39. Jahrestreffen der Society for Immunotherapy of Cancer (SITC) präsentiert. Die Daten werden auf der Unternehmenswebsite bereitgestellt, begleitet von einer Pressemitteilung, die die Ergebnisse analysiert.
- None.
- None.
Insights
This announcement about the upcoming presentation of Phase 1 clinical trial data for Anixa's breast cancer vaccine is not immediately impactful for investors. While clinical trial data is typically significant, this news merely announces the timing of data release on November 8, 2024, without providing any actual results or findings. The focus on triple negative breast cancer (TNBC) is noteworthy as it represents an area of high unmet medical need, but investors should wait for the actual data release to assess the vaccine's potential impact on Anixa's valuation and future prospects.
As previously announced, the presentation, titled "Phase I Trial of alpha-lactalbumin vaccine in high risk operable triple negative breast cancer (TNBC) and patients at high genetic risk for TNBC," will be presented at 12:15pm CT on November 8, 2024 at the SITC 39th Annual Meeting.
The poster presentation can be viewed starting at 12:15pm CT on November 8, 2024 at https://ir.anixa.com/events.
About Anixa Bioscience's Breast Cancer Vaccine
Anixa's breast cancer vaccine takes advantage of endogenously produced proteins that have a function at certain times in life, but then become "retired" and disappear from the body. One such protein is a breast-specific lactation protein, α-lactalbumin, which is no longer found post-lactation in normal, aging tissues, but is present in certain breast cancers. Activating the immune system against this "retired" protein provides preemptive immune protection against emerging breast tumors that express α-lactalbumin. The vaccine also contains an adjuvant that activates an innate immune response, which allows the immune system to mount a response against emerging tumors to prevent them from growing.
Initial Phase 1 data was presented at the San Antonio Breast Cancer Symposium in December 2023. The data showed no safety concerns, with protocol defined immune responses observed in a majority of patients.
The Phase 1 trial is conducted in collaboration with Cleveland Clinic and is funded by a grant from the
This vaccine technology was invented by the late Dr. Vincent Tuohy, who was the Mort and Iris November Distinguished Chair in Innovative Breast Cancer Research in the Department of Inflammation and Immunity at Cleveland Clinic's Lerner Research Institute. Cleveland Clinic exclusively licensed this technology to Anixa Biosciences. The Cleveland Clinic is entitled to royalties and other commercialization revenues from the Company.
About Anixa Biosciences, Inc.
Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. Anixa's therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor-T cell (CER-T) technology. The Company's vaccine portfolio includes vaccines being developed in collaboration with Cleveland Clinic to treat and prevent breast cancer and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms of cancer. Anixa's unique business model of partnering with world-renowned research institutions on all stages of development allows the Company to continually examine emerging technologies in complementary fields for further development and commercialization. To learn more, visit www.anixa.com or follow Anixa on Twitter, LinkedIn, Facebook and YouTube.
Forward-Looking Statements
Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect Anixa's current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release.
Contact:
Mike Catelani
President, COO & CFO
mcatelani@anixa.com
408-708-9808
View original content to download multimedia:https://www.prnewswire.com/news-releases/anixa-biosciences-announces-timing-of-public-release-of-data-from-the-phase-1-study-of-its-breast-cancer-vaccine-at-the-39th-society-for-immunotherapy-of-cancer-sitc-annual-meeting-302297172.html
SOURCE Anixa Biosciences, Inc.
FAQ
When will Anixa Biosciences (ANIX) release Phase 1 breast cancer vaccine trial data?
What type of cancer does Anixa Biosciences' (ANIX) vaccine target?